Crearene AG and Alzchem Group AG: Creatine in dialysis patients - clinical study started
Dialysis is a standard method for cleaning a patient’s blood in case of chronic kidney disease (CKD). Scientific research and studies have demonstrated that dialysis patients who already suffer from a substantially reduced creatine level in their body because of the chronic kidney malfunction are further depleted in their creatine levels by the dialysis process.
Creatine is a natural substance which occurs regularly in the body and plays a vital role as both a means of energy transport and energy supply in human cells. There is a certain amount of creatine which can be picked up via fish and meat, but using nutritional supplementation as an additional source of creatine has proven useful, e. g. in cases of higher body performance requirements. Yet creatine also plays an important role for chronically ill people.
A clinical study has been launched with support from Crearene AG as part of the research cooperation between Alzchem Group AG and Crearene AG which has been in place since August 2022. The study is expected to evaluate the feasibility of adding creatine into the dialysis process and to explore effects.
The cooperation partners expect results of the study by year end. Based on the combination of the patented know-how of Crearene, result on many years of research in the field of creatine, and the manufacturing excellence of Alzchem the partners hope to be able to help dialysis patients globally: Today there are already three million people treated for CKD – with a rising long term trend.
Press release regarding the research cooperation between the partners.